29
M
A
N
U
S
C
R
I
P
T
Figure 3. Cost-Effectiveness Analysis for PCSK9 Inhibitors
Figure 3. Cost-Effectiveness Analysis for PCSK9 Inhibitors
Conceptual relationship between the clinical effectiveness of PCSK9 inhibitor therapy,
measured in QALYs added compared with statin therapy, on the horizontal axis, and their
clinical value, measured in dollars per QALY added, on the vertical axis. e top curve
indicates the relationship at full U.S list price of PCSK9 inhibitor therapy ($14,000/y), the
middle curve indicates the relationship if the price were reduced by 50% (i.e., to $7,000/y),
and the bottom curve indicates the relationship if the price were reduced by 75% (i.e., to
$3,500/y). Reproduced from Hlatky et al. J Am Coll Cardiol. 2017;70:2677-87.
